Quarterly Financial Results for Q2 2026 – This 10-Q filing reports Zoetis Inc.'s financial performance for the six-month period ended June 30, 2026, and the three-month quarter ended June 30, 2026, compared to the same periods in 2025 Consolidated Financial Statements – Contains unaudited condensed consolidated balance sheets as of June 30, 2026 and December 31, 2025, along with statements of…

Our analysis rates this filing NEUTRAL. Zoetis Inc. presents a stable risk profile consistent with a mature, diversified pharmaceutical company. The identified accounting adjustment for lease accounting is routine and non-material, with prior period restatement already completed—indicating proper…

Concern level: MODERATE (3.8/10). Key factors: Accounting policy change requiring restatement of comparative periods (though non-material and already reflected); Standard pharmaceutical industry risks present but not specifically quantified in available disclosure; Derivative hedging complexity across multiple currencies suggests exposure to foreign exchange volatility.

Notable risk changes: Accounting principle revision disclosed for lease accounting in Q2 2025 comparative period - appears to be non-material technical adjustment with prior period restatement already completed; Filing structure shows extensive derivative hedging activities (cash flow and net investment hedges) across multiple currencies and geographies - indicates active but standard risk management; No material…

The model predicts ZTS will outperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.